The Gujarat Kidney and Super Speciality Hospital IPO has moved into the allotment phase after closing with a healthy overall response from investors. The public issue, worth about ₹251 crore, was subscribed over five times, driven largely by strong participation from retail investors. Subscription from institutional investors was comparatively moderate, reflecting a more cautious approach from larger funds.
The IPO was priced in a band of ₹108–₹114 per share, with the final issue price fixed at the upper end of ₹114. Investors who applied for the issue are now waiting for the basis of allotment, which is expected to be finalised shortly. Once completed, applicants can check their allotment status on the registrar’s website or through the BSE portal using their PAN or application number.
Shares allotted to successful applicants are expected to be credited to demat accounts before listing, while refunds to unsuccessful bidders will be processed during the same period. The company’s shares are scheduled to list on the BSE and NSE, marking its entry into the public markets.
Ahead of listing, the grey market premium (GMP) for the stock has remained flat or marginal. This indicates that market participants are expecting a muted or near-issue-price listing, rather than sharp gains on debut. A flat GMP often reflects balanced expectations, where investors are focusing more on long-term fundamentals than short-term listing profits.
Gujarat Kidney and Super Speciality Hospital operates a network of multi-speciality hospitals with a strong focus on renal care, along with associated pharmacies. The company has reported improving revenues and profitability, supported by expanded capacity and better operational efficiency in recent years.
The proceeds from the IPO will be used for business expansion and strategic initiatives. These include acquiring existing hospitals, setting up new facilities, investing in advanced medical technology, increasing stakes in subsidiaries, and reducing certain borrowings. The company aims to strengthen its presence in Gujarat and improve specialised healthcare delivery.
Overall, while the IPO has attracted solid retail interest, the absence of a strong grey market premium suggests a steady listing with limited upside in the short term. Investors and analysts will closely watch the stock’s performance after listing to assess how the market values the company’s growth plans and healthcare focus.
Also Read: Japan approves $785 bn budget, pledges fiscal discipline
